Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 1/29/2023
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Analysts rush to cut Intel (INTC) price targets following weaker than expected Q1 guidance
- Meta (META): Apple's privacy policy change 'no longer a drag on earnings', now a tailwind YoY - WSJ
- Lucid Group (LCID) doubles on Saudi rumors
- Lucid Group (LCID) halted again on volatility after 56% mid-day surge on rumors
- Bed Bath & Beyond (BBBY) Names Carol Flaton to Board of Directors
- Lucid Group (LCID) on Watch Following Chatter
- Hanryu Holdings (HRYU) Announces Proposed IPO
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Midday movers: American Express, Tesla, Intel and more
- Intel tumbles in premarket; Hasbro, Chevron also down
- After-hours movers: Intel sinks on humiliating guidance, Visa gains on earnings
- Midday movers: Tesla, Chevron, Southwest Airlines and more
- After-hours movers: Tesla ticks up on beat, Chevron jumps on massive buyback
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
February 8, 2022 4:05 PM ESTFourth Quarter 2021 Revenue of $24.2 Million and Full Year 2021 Revenue of $96.1 Million
Launch of QINLOCK® in Europe Underway
Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Data Expected in 2H 2022
Phase 1 Single Agent Dose Escalation Data for DCC-3116 Expected in 2H 2022; Initiation of Phase 1 Combination Dose Escalation Cohorts Expected in 2H 2022
New Development Candidate from Pan-RAF Research Program Expected in 2022
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced... More
